FY2025 results: profit swings to £1.6m as margins tighten up
Cambridge Nutritional Sciences PLC (AIM: CNSL) has posted a clean swing into profit for the year ended 31 March 2025. Total income rose despite lower sales, margins improved, costs were trimmed, and a long‑running dispute with the Department of Health and Social Care (DHSC) was resolved in CNSL’s favour.
The headline is a 310% improvement in profit before tax to £1.6 million versus a £0.7 million loss last year, helped by the £2.5 million DHSC settlement booked as exceptional income. Under the bonnet, the core business kept discipline: gross margin moved up to 65.3% and adjusted EBITDA more than doubled to £0.4 million.
Key numbers investors should know
| Metric | FY2025 | FY2024 | Comment |
|---|---|---|---|
| Total income | £11.1m | £9.9m | Up 12.7%, includes £2.5m DHSC exceptional income |
| Revenue | £8.3m | £9.8m | Down 14.8% on overstocking and distributor loss |
| Gross margin | 65.3% | 61.9% | Operational gains and mix shift |
| Adjusted EBITDA | £0.4m | £0.2m | More than doubled |
| Profit before tax | £1.6m | £0.7m loss | Statutory, boosted by exceptional income |
| Adjusted profit before tax | £0.04m | £0.3m loss | Near breakeven on an adjusted basis |
| Cash and deposits | £4.9m | £5.4m | Down 10.6% |
| EPS | 0.7p | (0.1)p | Back in positive territory |
Quick jargon buster: gross margin is the profit after manufacturing costs. EBITDA is earnings before interest, tax, depreciation and amortisation, a proxy for cash earnings from operations. “Adjusted” strips out one‑offs like legal settlements and share‑based payments.
What drove the swing to profit?
DHSC settlement cleared the decks
The big swing factor was the final settlement of the DHSC dispute. CNSL recognised £2.5 million of income and removed the £2.5 million deferred income liability. That, plus tight cost control and better manufacturing yields, turned the P&L around. The only sting in the tail was £0.4 million of legal costs and a £35,000 HSE fine related to a historic matter, both treated as exceptional items.
Operational improvements are real and repeatable
- Lab productivity up, with guaranteed customer turnaround times halved.
- Scrap down 41% and automation investments now in place.
- Net operating costs before exceptionals fell to £5.8 million from £6.6 million.
- Headcount optimised to 84 from 94 while adding key hires in sales, finance and operations.
These improvements underpinned the jump in gross margin to 65.3% from 61.9% and helped adjusted EBITDA reach £0.4 million despite lower sales.
Sales mix: UK resilient, overseas softer
- UK lab service revenue rose 9% to £1.6 million, helped by direct‑to‑consumer channels.
- FoodPrint sales were £4.8 million, down 20% after customers worked through prior year overstocks.
- Food Detective was £1.8 million, down 14%.
- India grew 25%, while the Americas fell 37% after a distributor lost a client. Africa & Middle East fell 41% and Asia & Far East fell 15%.
One customer accounted for 14.9% of revenue. Worth watching, but not unusual for a specialist diagnostics business.
Cash, balance sheet and runway
Cash and deposits stood at £4.9 million at year end, down from £5.4 million. The Group reported a small operating cash outflow of £0.06 million as the £2.5 million DHSC release moved from the balance sheet to the income statement. Net current assets were £5.6 million and total equity climbed to £11.4 million.
On going concern, management’s reverse stress tests suggest revenue could fall a further 45% and gross margin shrink by 11 percentage points before cash resources are exhausted. That is a decent buffer for a business of this size.
Strategy and near‑term catalysts
Building the platform for growth
- New leadership team now complete, including CEO James Cooper and CFO Ajay Patel.
- New Global Sales Director hired to expand partner networks and pipelines.
- Electronic Quality Management System implemented and a new LIMS (Laboratory Information Management System) is underway to support UK growth this calendar year.
- IVDR project progressing to ensure CE mark compliance well ahead of the 2029 deadline, easing European and CE‑recognised market access.
- MyHealthTracker app rolled out to UK practitioners to support interpretation and engagement.
The commercial focus is clear: deepen UK penetration, re‑energise Europe and push into the USA while partnering with labs internationally. Management flags that international lab partnerships take time to convert, with the heavier benefits expected over the next two years. The stated aim is to deliver notable sales growth and further adjusted EBITDA improvement in FY2026.
What I like vs what worries me
Positives
- Profitability returned. Statutory PBT of £1.6 million and positive EPS of 0.7p are confidence builders.
- Quality of operations. 41% scrap reduction and higher margins show strong execution.
- Legal overhang resolved. DHSC dispute is closed and the HSE matter is settled.
- Disciplined cost base. Overheads down £0.6 million excluding exceptionals, with reinvestment being paced.
- Healthy cash buffer and robust stress test disclosure.
Watch‑fors
- Revenue fell 14.8%. The swing to profit was helped by exceptional income, while adjusted profit before tax was only £0.04 million. Sustained sales growth now needs to do the heavy lifting.
- Geographic volatility. Sharp declines in the Americas, Africa & Middle East and parts of Asia highlight distribution risk.
- Customer concentration at 14.9% of revenue and reliance on FoodPrint and FoodDetective brands.
- Cash down 10.6% year on year. Investment is necessary but must be matched by delivery from the enlarged sales team.
Product segment snapshot
| Product/Service | FY2025 | FY2024 | Change |
|---|---|---|---|
| FoodPrint | £4.841m | £6.016m | -20% |
| Food Detective | £1.794m | £2.082m | -14% |
| CNSLab service | £1.634m | £1.500m | +9% |
| Other | £0.061m | £0.176m | -65% |
Outlook in plain English
Management is upbeat. The operational engine is humming, the leadership bench is filled, and the sales team is building a pipeline across the UK, Europe and the USA. The company expects pipeline conversion through FY2026, with the larger benefits from international lab partnerships flowing over the next two years. Given the evidence of margin control and productivity improvements, that feels achievable if demand strengthens and distributor issues in the Americas are resolved.
My take for retail investors
This was a “reset and rebuild” year that happened to land a sizeable legal win. The core business is now tighter, faster and more profitable per unit. The next leg of the story depends on converting the pipeline into revenue growth so adjusted profits follow suit without the help of exceptionals.
If you are following CNSL, the key things to watch in FY2026 are: sequential revenue growth, especially outside the UK; continued gross margin resilience above 60%; cash stability while investment continues; and evidence of multi‑market partner wins. Deliver those, and FY2025 may be remembered as the year the foundations were laid for a more scalable diagnostics business.
